Field efficacy of a combined use of Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae vaccines in growing pigs

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

4 Scopus Citations
View graph of relations



Original languageEnglish
Pages (from-to)13-24
Journal / PublicationPreventive Veterinary Medicine
Issue number1
Publication statusPublished - 12 Mar 1999
Externally publishedYes


The effectiveness of simultaneous administration of commercial Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae vaccines was tested in an indoor commercial piggery which had experienced continuing respiratory-disease problems confirmed as due to both of these pathogens. Piglets were randomly assigned in equal numbers to vaccination and control groups, and each vaccine was administered at a separate site to assigned piglets at two and four weeks of age. Live weight of vaccinates immediately prior to slaughter was 2.49 kg higher (p = 0.04) than for controls at equal mean slaughter age of 132 days. Average daily gain (ADG) from 16 weeks to slaughter of vaccinates was also significantly higher (33 g/day) than in controls (p = 0.05). Daily gain was not significantly different in younger age groups. Active enzootic pneumonia lesions were more likely in control than in vaccinated pigs. There were no significant differences between vaccination groups with regard to severity of pleurisy or presence of pleuropneumonia lesions at slaughter. Log-linear modelling was used to test the statistical association between vaccination, enzootic-pneumonia lesions, pleurisy lesions and pleuropneumonia lesions. It showed a reduction in the severity of enzootic pneumonia lesions for vaccinated pigs, and the presence of pleuropneumonia lesions increased the likelihood of pleurisy lesions. No other association was significant, and no evidence of synergy between the vaccines in influencing lesion severity for pleuropneumonia was detected (within the limitations set by the trial design).

Research Area(s)

  • Actinobacillus pleuropneumoniae, Clinical trial, Mycoplasma hyopneumoniae, Pig - microbiological diseases, Pneumonia, Respiratory disease, Vaccination